Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 381.5 JPY 2.12% Market Closed
Market Cap: ¥562.5B

EV/S

1.5
Current
33%
Cheaper
vs 3-y average of 2.2

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.5
=
Enterprise Value
¥489.9B
/
Revenue
¥335.8B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.5
=
Enterprise Value
¥489.9B
/
Revenue
¥335.8B

Valuation Scenarios

Rohto Pharmaceutical Co Ltd is trading below its 3-year average

If EV/S returns to its 3-Year Average (2.2), the stock would be worth ¥3 536.25 (48% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-41%
Maximum Upside
+57%
Average Upside
10%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 1.5 ¥2 381.5
0%
3-Year Average 2.2 ¥3 536.25
+48%
5-Year Average 2.3 ¥3 737.82
+57%
Industry Average 0.9 ¥1 395.22
-41%
Country Average 1.1 ¥1 811.4
-24%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥489.9B
/
Jan 2026
¥335.8B
=
1.5
Current
¥489.9B
/
Mar 2026
¥342.2B
=
1.4
Forward
¥489.9B
/
Mar 2027
¥361.5B
=
1.4
Forward
¥489.9B
/
Mar 2028
¥377.7B
=
1.3
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
JP
Rohto Pharmaceutical Co Ltd
TSE:4527
538.1B JPY 1.5 15.6
FR
L'Oreal SA
PAR:OR
201.5B EUR 4.6 32.9
UK
Unilever PLC
LSE:ULVR
93.4B GBP 2.6 11.3
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
5.6T INR 8.3 37.6
UK
HALEON PLC
LSE:HLN
31.6B GBP 3.5 19
US
Estee Lauder Companies Inc
NYSE:EL
28.1B USD 2.2 -158.1
DE
Beiersdorf AG
XETRA:BEI
15.8B EUR 1.4 16.8
JP
Kao Corp
TSE:4452
2.7T JPY 1.5 22.2
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
1.2T INR 7.8 64.1
CA
Relevium Technologies Inc
XTSX:RLV
12.2B CAD 855.7 -4 624.4
IN
Dabur India Ltd
NSE:DABUR
815.9B INR 5.8 43.3
P/E Multiple
Earnings Growth PEG
JP
Rohto Pharmaceutical Co Ltd
TSE:4527
Average P/E: 29.2
15.6
6%
2.6
FR
L'Oreal SA
PAR:OR
32.9
13%
2.5
UK
Unilever PLC
LSE:ULVR
11.3
-6%
N/A
IN
Hindustan Unilever Ltd
NSE:HINDUNILVR
37.6
7%
5.4
UK
HALEON PLC
LSE:HLN
19
11%
1.7
US
Estee Lauder Companies Inc
NYSE:EL
Negative Multiple: -158.1 N/A N/A
DE
Beiersdorf AG
XETRA:BEI
16.8
6%
2.8
JP
Kao Corp
TSE:4452
22.2
10%
2.2
IN
Godrej Consumer Products Ltd
NSE:GODREJCP
64.1
18%
3.6
CA
Relevium Technologies Inc
XTSX:RLV
Negative Multiple: -4 624.4 N/A N/A
IN
Dabur India Ltd
NSE:DABUR
43.3
11%
3.9

Market Distribution

In line with most companies in Japan
Percentile
60th
Based on 5 140 companies
60th percentile
1.5
Low
0 — 0.7
Typical Range
0.7 — 2
High
2 —
Distribution Statistics
Japan
Min 0
30th Percentile 0.7
Median 1.1
70th Percentile 2
Max 12 107 466

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
562.5B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
2 162.98 JPY
Overvaluation 9%
Intrinsic Value
Price ¥2 381.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett